ID   ABL2_HUMAN              Reviewed;        1182 AA.
AC   P42684; A0M8X0; Q5T0X6; Q5W0C5; Q6NZY6; Q7Z301;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   02-NOV-2010, entry version 125.
DE   RecName: Full=Tyrosine-protein kinase ABL2;
DE            EC=2.7.10.2;
DE   AltName: Full=Abelson murine leukemia viral oncogene homolog 2;
DE   AltName: Full=Abelson-related gene protein;
DE   AltName: Full=Tyrosine-protein kinase ARG;
GN   Name=ABL2; Synonyms=ABLL, ARG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS IA AND IB).
RX   MEDLINE=90332670; PubMed=2198571; DOI=10.1073/pnas.87.15.5802;
RA   Kruh G.D., Perego R., Miki T., Aaronson S.A.;
RT   "The complete coding sequence of arg defines the Abelson subfamily of
RT   cytoplasmic tyrosine kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5802-5806(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Uterine endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-930; MET-946;
RP   ARG-996; ASN-1085 AND ALA-1101.
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IC).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 343-469.
RX   PubMed=3787260; DOI=10.1126/science.3787260;
RA   Kruh G.D., King C.R., Kraus M.H., Popescu N.C., Amsbaugh S.C.,
RA   McBride W.O., Aaronson S.A.;
RT   "A novel human gene closely related to the abl proto-oncogene.";
RL   Science 234:1545-1548(1986).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-310; TYR-439; THR-440
RP   AND TYR-515, AND MASS SPECTROMETRY.
RX   MEDLINE=22426906; PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [9]
RP   INTERACTION WITH RIN1, FUNCTION, AND ENZYME REGULATION.
RX   PubMed=15886098; DOI=10.1016/j.cub.2005.03.049;
RA   Hu H., Bliss J.M., Wang Y., Colicelli J.;
RT   "RIN1 is an ABL tyrosine kinase activator and a regulator of
RT   epithelial-cell adhesion and migration.";
RL   Curr. Biol. 15:815-823(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203 AND SER-631, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH PSMA7.
RX   PubMed=16678104; DOI=10.1016/j.molcel.2006.04.007;
RA   Liu X., Huang W., Li C., Li P., Yuan J., Li X., Qiu X.B., Ma Q.,
RA   Cao C.;
RT   "Interaction between c-Abl and Arg tyrosine kinases and proteasome
RT   subunit PSMA7 regulates proteasome degradation.";
RL   Mol. Cell 22:317-327(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-439, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631; SER-783; SER-817
RP   AND SER-936, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817 AND SER-820, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-116; SER-203; TYR-231;
RP   SER-275; SER-602; SER-620; SER-631; SER-671; TYR-718; SER-820;
RP   THR-864; SER-915 AND SER-936, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620; SER-631; SER-633;
RP   SER-655; SER-817; SER-820; SER-915 AND SER-936, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620; SER-631; SER-783;
RP   SER-817; THR-818; SER-819; SER-820; SER-936 AND THR-938, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-439, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96; SER-620; SER-631;
RP   TYR-683; TYR-718; SER-781; THR-784; THR-815; SER-817; SER-819; SER-820
RP   AND SER-936, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817; SER-820 AND
RP   SER-936, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   STRUCTURE BY NMR OF 163-268.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human ABL2 SH2 domain.";
RL   Submitted (FEB-2008) to the PDB data bank.
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 279-546 IN COMPLEX WITH
RP   GLEEVEC.
RG   Structural genomics consortium (SGC);
RT   "The crystal structure of human ABL2 in complex with Gleevec.";
RL   Submitted (APR-2009) to the PDB data bank.
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-78; GLN-99; ILE-519; SER-769;
RP   ARG-930 AND ARG-996, AND VARIANT [LARGE SCALE ANALYSIS] THR-12
RP   (ISOFORM 4).
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Regulates cytoskeleton remodeling during cell
CC       differentiation, cell division and cell adhesion. Localizes to
CC       dynamic actin structures, and phosphorylates CRK and CRKL, DOK1,
CC       and other proteins controlling cytoskeleton dynamics.
CC       Phosphorylates PSMA7 that leads to an inhibition of proteasomal
CC       activity and cell cycle transition blocks.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Magnesium or manganese.
CC   -!- ENZYME REGULATION: Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region,
CC       interactions of the amino-terminal cap, and contributions from an
CC       amino-terminal myristoyl group and phospholipids. Activated by
CC       autophosphorylation as well as by SRC-family kinase-mediated
CC       phosphorylation. Activated by RIN1 binding to the SH2 and SH3
CC       domains. Inhibited by imatinib mesylate (Gleevec) which is used
CC       for the treatment of chronic myeloid leukemia (CML).
CC   -!- SUBUNIT: Interacts with PSMA7.
CC   -!- INTERACTION:
CC       P46108:CRK; NbExp=2; IntAct=EBI-1102694, EBI-886;
CC       Q04929:CRK (xeno); NbExp=1; IntAct=EBI-1102694, EBI-1102801;
CC       P06241:FYN; NbExp=1; IntAct=EBI-1102694, EBI-515315;
CC       P62993:GRB2; NbExp=1; IntAct=EBI-1102694, EBI-401755;
CC       P16333:NCK1; NbExp=1; IntAct=EBI-1102694, EBI-389883;
CC       P27986:PIK3R1; NbExp=1; IntAct=EBI-1102694, EBI-79464;
CC       P19174:PLCG1; NbExp=2; IntAct=EBI-1102694, EBI-79387;
CC       Q13671:RIN1; NbExp=2; IntAct=EBI-1102694, EBI-366017;
CC       P12931:SRC; NbExp=1; IntAct=EBI-1102694, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=IB;
CC         IsoId=P42684-1; Sequence=Displayed;
CC       Name=IA;
CC         IsoId=P42684-2; Sequence=VSP_004961;
CC       Name=IC;
CC         IsoId=P42684-3; Sequence=VSP_017112;
CC       Name=4;
CC         IsoId=P42684-4; Sequence=VSP_021307, VSP_021308;
CC         Note=No experimental confirmation available. Variant in
CC         position: 12:S->T (in dbSNP:rs1318056);
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Phosphorylated upon DNA damage, probably by ATM or ATR.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ABL subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD98092.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABL2ID226.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abl2/";
CC   -!- WEB RESOURCE: Name=CGP resequencing studies;
CC       URL="http://www.sanger.ac.uk/perl/genetics/CGP/cgp_viewer?action=gene&ln=ABL2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M35296; AAA35553.1; -; mRNA.
DR   EMBL; BX538317; CAD98092.1; ALT_INIT; mRNA.
DR   EMBL; DQ009672; AAY16984.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAH70921.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAH70921.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAH70921.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAH70925.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAH70925.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAH70925.1; JOINED; Genomic_DNA.
DR   EMBL; AL359179; CAI15584.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAI15584.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI15584.1; JOINED; Genomic_DNA.
DR   EMBL; AL359179; CAI15585.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAI15585.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI15585.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI13566.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAI13566.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAI13566.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI13570.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAI13570.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAI13570.1; JOINED; Genomic_DNA.
DR   EMBL; CH471067; EAW91040.1; -; Genomic_DNA.
DR   EMBL; BC065912; AAH65912.1; -; mRNA.
DR   IPI; IPI00329488; -.
DR   IPI; IPI00383728; -.
DR   IPI; IPI00719587; -.
DR   IPI; IPI00745593; -.
DR   PIR; A35962; A35962.
DR   PIR; B35962; B35962.
DR   RefSeq; NP_001129472.1; -.
DR   RefSeq; NP_001129473.1; -.
DR   RefSeq; NP_001161711.1; -.
DR   RefSeq; NP_005149.4; -.
DR   RefSeq; NP_009298.1; -.
DR   UniGene; Hs.159472; -.
DR   PDB; 2ECD; NMR; -; A=163-268.
DR   PDB; 2KK1; NMR; -; A=1058-1182.
DR   PDB; 3GVU; X-ray; 2.05 A; A=279-546.
DR   PDB; 3HMI; X-ray; 1.65 A; A=279-546.
DR   PDB; 3NSV; X-ray; 2.81 A; A/B/C=279-546.
DR   PDBsum; 2ECD; -.
DR   PDBsum; 2KK1; -.
DR   PDBsum; 3GVU; -.
DR   PDBsum; 3HMI; -.
DR   PDBsum; 3NSV; -.
DR   ProteinModelPortal; P42684; -.
DR   SMR; P42684; 108-558.
DR   DIP; DIP-91N; -.
DR   IntAct; P42684; 38.
DR   MINT; MINT-1347081; -.
DR   STRING; P42684; -.
DR   PhosphoSite; P42684; -.
DR   PRIDE; P42684; -.
DR   Ensembl; ENST00000367623; ENSP00000356595; ENSG00000143322.
DR   GeneID; 27; -.
DR   KEGG; hsa:27; -.
DR   UCSC; uc001gmg.2; human.
DR   UCSC; uc001gmh.2; human.
DR   UCSC; uc001gmi.2; human.
DR   UCSC; uc001gmj.2; human.
DR   CTD; 27; -.
DR   GeneCards; GC01M179068; -.
DR   H-InvDB; HIX0001374; -.
DR   HGNC; HGNC:77; ABL2.
DR   HPA; CAB017106; -.
DR   HPA; HPA001866; -.
DR   MIM; 164690; gene.
DR   PharmGKB; PA24414; -.
DR   eggNOG; prNOG11298; -.
DR   HOGENOM; HBG446901; -.
DR   HOVERGEN; HBG004162; -.
DR   InParanoid; P42684; -.
DR   OMA; QEANLVP; -.
DR   OrthoDB; EOG937V10; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Reactome; REACT_18266; Axon guidance.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01254; Dasatinib.
DR   NextBio; 89; -.
DR   ArrayExpress; P42684; -.
DR   Bgee; P42684; -.
DR   CleanEx; HS_ABL2; -.
DR   Genevestigator; P42684; -.
DR   GermOnline; ENSG00000143322; Homo sapiens.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR015015; F-actin_binding.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR020700; Tyr_kinase_non-rcpt_Abl.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF144; Tyr_kinase_non-rcpt_Abl; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF08919; F_actin_bind; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00808; FABD; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Kinase; Lipoprotein;
KW   Magnesium; Manganese; Metal-binding; Myristate; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2   1182       Tyrosine-protein kinase ABL2.
FT                                /FTId=PRO_0000088052.
FT   DOMAIN      107    167       SH3.
FT   DOMAIN      173    263       SH2.
FT   DOMAIN      288    539       Protein kinase.
FT   NP_BIND     294    302       ATP (By similarity).
FT   NP_BIND     362    368       ATP (By similarity).
FT   REGION        2    106       CAP.
FT   MOTIF       427    451       Kinase activation loop (By similarity).
FT   MOTIF       658    660       Nuclear localization signal (Potential).
FT   COMPBIAS    561    564       Poly-Ser.
FT   COMPBIAS    732    739       Poly-Gly.
FT   COMPBIAS    843   1055       Pro-rich.
FT   COMPBIAS    984    988       Poly-Pro.
FT   ACT_SITE    409    409       Proton acceptor (By similarity).
FT   BINDING     317    317       ATP (By similarity).
FT   MOD_RES      71     71       Phosphoserine.
FT   MOD_RES      96     96       Phosphoserine.
FT   MOD_RES     116    116       Phosphotyrosine.
FT   MOD_RES     203    203       Phosphoserine.
FT   MOD_RES     231    231       Phosphotyrosine.
FT   MOD_RES     272    272       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     275    275       Phosphoserine.
FT   MOD_RES     299    299       Phosphotyrosine (By similarity).
FT   MOD_RES     303    303       Phosphotyrosine (By similarity).
FT   MOD_RES     310    310       Phosphotyrosine.
FT   MOD_RES     439    439       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     440    440       Phosphothreonine.
FT   MOD_RES     492    492       Phosphoserine (By similarity).
FT   MOD_RES     515    515       Phosphotyrosine.
FT   MOD_RES     602    602       Phosphoserine.
FT   MOD_RES     620    620       Phosphoserine.
FT   MOD_RES     631    631       Phosphoserine.
FT   MOD_RES     633    633       Phosphoserine.
FT   MOD_RES     655    655       Phosphoserine.
FT   MOD_RES     671    671       Phosphoserine.
FT   MOD_RES     683    683       Phosphotyrosine.
FT   MOD_RES     718    718       Phosphotyrosine.
FT   MOD_RES     781    781       Phosphoserine.
FT   MOD_RES     783    783       Phosphoserine.
FT   MOD_RES     784    784       Phosphothreonine.
FT   MOD_RES     815    815       Phosphothreonine.
FT   MOD_RES     817    817       Phosphoserine.
FT   MOD_RES     818    818       Phosphothreonine.
FT   MOD_RES     819    819       Phosphoserine.
FT   MOD_RES     820    820       Phosphoserine.
FT   MOD_RES     864    864       Phosphothreonine.
FT   MOD_RES     915    915       Phosphoserine.
FT   MOD_RES     936    936       Phosphoserine.
FT   MOD_RES     938    938       Phosphothreonine.
FT   LIPID         2      2       N-myristoyl glycine (By similarity).
FT   VAR_SEQ       1     73       MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRT
FT                                TETGFNIFTQHDHFASCVEDGFEGDKTGGSSP -> MVLGT
FT                                VLLPPNSYGRDQDTSLCCLCTEASESALPDLT (in
FT                                isoform 4).
FT                                /FTId=VSP_021307.
FT   VAR_SEQ       1     73       MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRT
FT                                TETGFNIFTQHDHFASCVEDGFEGDKTGGSSP -> MVLGT
FT                                VLLPPNTYGRDQDTSLCCLCTEASESALPDLT (in
FT                                isoform IA).
FT                                /FTId=VSP_004961.
FT   VAR_SEQ       1     52       MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRT
FT                                TETGFNIFTQH -> MVLGTVLLPPNSYGRDQDTSLCCLCT
FT                                EASESALPDLT (in isoform IC).
FT                                /FTId=VSP_017112.
FT   VAR_SEQ     688    790       Missing (in isoform 4).
FT                                /FTId=VSP_021308.
FT   VARIANT      78     78       R -> H (in dbSNP:rs55655202).
FT                                /FTId=VAR_055411.
FT   VARIANT      99     99       E -> Q (somatic mutation in a breast
FT                                cancer sample).
FT                                /FTId=VAR_055412.
FT   VARIANT     519    519       R -> I (somatic mutation in a lung
FT                                squamous cell carcinoma).
FT                                /FTId=VAR_055413.
FT   VARIANT     769    769       T -> S (in dbSNP:rs55892721).
FT                                /FTId=VAR_055414.
FT   VARIANT     930    930       K -> R (in dbSNP:rs17277288).
FT                                /FTId=VAR_029232.
FT   VARIANT     946    946       V -> M (in dbSNP:rs28913889).
FT                                /FTId=VAR_029233.
FT   VARIANT     996    996       P -> R (in dbSNP:rs28913890).
FT                                /FTId=VAR_029234.
FT   VARIANT    1085   1085       S -> N (in dbSNP:rs28913891).
FT                                /FTId=VAR_029235.
FT   VARIANT    1101   1101       T -> A (in dbSNP:rs28913892).
FT                                /FTId=VAR_029236.
FT   CONFLICT    343    344       NL -> TI (in Ref. 7).
FT   CONFLICT    981    981       K -> R (in Ref. 2; CAD98092).
FT   STRAND      171    177
FT   HELIX       180    188
FT   STRAND      194    203
FT   STRAND      206    212
FT   STRAND      217    220
FT   STRAND      226    228
FT   HELIX       241    250
FT   STRAND      255    257
SQ   SEQUENCE   1182 AA;  128343 MW;  ED93869BC2B14FAA CRC64;
     MGQQVGRVGE APGLQQPQPR GIRGSSAARP SGRRRDPAGR TTETGFNIFT QHDHFASCVE
     DGFEGDKTGG SSPEALHRPY GCDVEPQALN EAIRWSSKEN LLGATESDPN LFVALYDFVA
     SGDNTLSITK GEKLRVLGYN QNGEWSEVRS KNGQGWVPSN YITPVNSLEK HSWYHGPVSR
     SAAEYLLSSL INGSFLVRES ESSPGQLSIS LRYEGRVYHY RINTTADGKV YVTAESRFST
     LAELVHHHST VADGLVTTLH YPAPKCNKPT VYGVSPIHDK WEMERTDITM KHKLGGGQYG
     EVYVGVWKKY SLTVAVKTLK EDTMEVEEFL KEAAVMKEIK HPNLVQLLGV CTLEPPFYIV
     TEYMPYGNLL DYLRECNREE VTAVVLLYMA TQISSAMEYL EKKNFIHRDL AARNCLVGEN
     HVVKVADFGL SRLMTGDTYT AHAGAKFPIK WTAPESLAYN TFSIKSDVWA FGVLLWEIAT
     YGMSPYPGID LSQVYDLLEK GYRMEQPEGC PPKVYELMRA CWKWSPADRP SFAETHQAFE
     TMFHDSSISE EVAEELGRAA SSSSVVPYLP RLPILPSKTR TLKKQVENKE NIEGAQDATE
     NSASSLAPGF IRGAQASSGS PALPRKQRDK SPSSLLEDAK ETCFTRDRKG GFFSSFMKKR
     NAPTPPKRSS SFREMENQPH KKYELTGNFS SVASLQHADG FSFTPAQQEA NLVPPKCYGG
     SFAQRNLCND DGGGGGGSGT AGGGWSGITG FFTPRLIKKT LGLRAGKPTA SDDTSKPFPR
     SNSTSSMSSG LPEQDRMAMT LPRNCQRSKL QLERTVSTSS QPEENVDRAN DMLPKKSEES
     AAPSRERPKA KLLPRGATAL PLRTPSGDLA ITEKDPPGVG VAGVAAAPKG KEKNGGARLG
     MAGVPEDGEQ PGWPSPAKAA PVLPTTHNHK VPVLISPTLK HTPADVQLIG TDSQGNKFKL
     LSEHQVTSSG DKDRPRRVKP KCAPPPPPVM RLLQHPSICS DPTEEPTALT AGQSTSETQE
     GGKKAALGAV PISGKAGRPV MPPPQVPLPT SSISPAKMAN GTAGTKVALR KTKQAAEKIS
     ADKISKEALL ECADLLSSAL TEPVPNSQLV DTGHQLLDYC SGYVDCIPQT RNKFAFREAV
     SKLELSLQEL QVSSAAAGVP GTNPVLNNLL SCVQEISDVV QR
//
